US 12,258,362 B2
Processes for preparing phosphorodiamidate morpholino oligomers
Baozhong Cai, Cambridge, MA (US); Mitchell Martini, Cambridge, MA (US); Ross Shimabuku, Cambridge, MA (US); and Katie Thomas, Cambridge, MA (US)
Assigned to Sarepta Therapeutics, Inc.
Filed by Sarepta Therapeutics, Inc., Cambridge, MA (US)
Filed on Feb. 8, 2021, as Appl. No. 17/169,611.
Application 17/169,611 is a continuation of application No. 16/302,443, granted, now 10,961,262, previously published as PCT/US2017/034284, filed on May 24, 2017.
Claims priority of provisional application 62/357,134, filed on Jun. 30, 2016.
Claims priority of provisional application 62/340,953, filed on May 24, 2016.
Prior Publication US 2022/0340605 A1, Oct. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07F 9/06 (2006.01); A61K 31/675 (2006.01); A61P 21/00 (2006.01); C07F 9/6558 (2006.01); C07F 9/6561 (2006.01)
CPC C07F 9/062 (2013.01) [C07F 9/65583 (2013.01); C07F 9/65616 (2013.01)] 5 Claims
 
1. A compound of Formula (A9):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
n is an integer from 10 to 40;
R1 is a support-medium;
R3 is selected from the group consisting of hydrogen, trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl; and
R4 is, independently at each occurrence, selected from the group consisting of:

OG Complex Work Unit Chemistry